Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study
Presented by Dr. Thomas Martin, this IMROZ subgroup analysis demonstrated that adding isatuximab to standard VRd therapy improved progression-free survival and deepened responses in transplant-ineligible patients with newly diagnosed multiple myeloma and 1q21+ status, a high-risk cytogenetic subgroup.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.